ASLAN Pharmaceuticals Limited (ASLN)

$ 0.912
-0.00 (-0.30%)
Symbol ASLN
Price $ 0.912
Beta 2.329
Volume Avg. 0.34M
Market Cap 0.063B
Shares () -
52 Week Range 0.81-6.75
1y Target Est -
DCF Unlevered ASLN DCF ->
DCF Levered ASLN LDCF ->
ROE -69.26% Strong Sell
ROA -20.22% Sell
Operating Margin -
Debt / Equity 54.42% Buy
P/E -
P/B 0.94 Buy


Consensus EPS

Upgrades & Downgrades

Latest ASLN news

Dr. Carl Alan Jason Morton Firth
Nasdaq Global Market

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.